A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis

Infectious Diseases and Therapy

Volumn 2, Issue 2, 2013, Pages 123-144

  Fox, Gregory J ^a   Menzies, Dick ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Antitubercular agents; Bedaquiline; Drug resistant tuberculosis; Extensively drug resistant; Multidrug resistant tuberculosis; TMC207; Tuberculosis

Indexed keywords

BEDAQUILINE; CYTOCHROME P450 3A4; PLACEBO;

ABDOMINAL PAIN; BACTERICIDAL ACTIVITY; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EVIDENCE BASED PRACTICE; GASTRITIS; HEADACHE; HEMOLYTIC ANEMIA; HEPATITIS; HUMAN; INFORMATION PROCESSING; INSOMNIA; LIVER CIRRHOSIS; LIVER DISEASE; MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA AND VOMITING; PANCREATITIS; PHLEBITIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; TREATMENT RESPONSE;

EID: 84977098261     PISSN: 21938229     EISSN: 21936382     Source Type: Journal    
DOI: 10.1007/s40121-013-0009-3     Document Type: Review

References (75)

1. World Health Organization. Global tuberculosis control 2012. Geneva: 2012. http://www. who. int/tb/publications/global_report/en/. Accessed on 1 May 2013.
2. World Health Organization. Treatment of tuberculosis guidelines. Geneva: 2010. http://www. who. int/tb/features_archive/new_treatment_guidelines_may2010/en/index. html. Accessed on 1 May 2013.
3. Keshavjee S, Farmer PE. Tuberculosis, drug resistance, and the history of modern medicine. New Engl J Med. 2012;367: 931-6.
4. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva 2011. http://whqlibdoc. who. int/publications/2011/9789241501583_eng. pdf. Accessed on 1 May 2013.
5. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9, 153 patients. PLoS Med. 2012;9: e1001300.
6. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9: 153-61.
7. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2009;4: e6914.
8. Migliori GB, Sotgiu G, Gandhi NR, et al. The collaborative group for meta-analysis of individual patient data in MDR-TB. Drug resistance beyond XDR-TB: results from a large individual patient data meta-analysis. Eur Respir J. 2013;42: 169-79.
9. The Stop TB Partnership. The Global Plan to Stop TB 2011-2015. Geneva 2010. http://www. stoptb. org/assets/documents/global/plan/TB_GlobalPlanToStopTB2011-2015. pdf. Accessed on 1 May 2013.
10. United States Food and Drug Administration. 2012. http://www. fda. gov/NewsEvents/Newsroom/PressAnnouncements/ucm333695. htm. Accessed on 1 May 2013.
11. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. http://www. who. int/tb/challenges/mdr/bedaquiline/en/index. html. Accessed on 1 May 2013.
12. Avorn J. Approval of a tuberculosis drug based on a paradoxical surrogate measure. JAMA. 2013;309: 1349-50.
13. Cohen J. Infectious disease. Approval of novel TB drug celebrated-with restraint. Science. 2013;339: 130.
14. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005;307: 223-7.
15. US Food and Drug Administration. Briefing Package: NDA 204-384: Sirturo. 2012. http://www. fda. gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM329258. pdf. Accessed on 1 May 2013.
16. Koul A, Vranckx L, Dendouga N, et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem. 2008;283: 25273-80.
17. Janssen Briefing Document. TMC207 (bedaquiline): Treatment of patients with MDR-TB: NDA 204-384. US Food and Drug Administration Website. 2012. http://www. fda. gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM329260. pdf. Accessed on 1 May 2013.
18. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360: 2397-405.
19. Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother. 2012;56: 3271-6.
20. Saga Y, Motoki R, Makino S, Shimizu Y, Kanai M, Shibasaki M. Catalytic asymmetric synthesis of R207910. J Am Chem Soc. 2010;132: 7905-7.
21. Biukovic G, Basak S, Manimekalai MS, et al. Variations of subunit varepsilon of the Mycobacterium tuberculosis F1Fo ATP synthase and a novel model for mechanism of action of the tuberculosis drug TMC207. Antimicrob Agents Chemother. 2013;57: 168-76.
22. Haagsma AC, Podasca I, Koul A, et al. Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase. PLoS One. 2011;6: e23575.
23. Guillemont J, Meyer C, Poncelet A, Bourdrez X, Andries K. Diarylquinolines, synthesis pathways and quantitative structure-activity relationship studies leading to the discovery of TMC207. Future Med Chem. 2011;3: 1345-60.
24. Upadhayaya RS, Vandavasi JK, Kardile RA, et al. Novel quinoline and naphthalene derivatives as potent antimycobacterial agents. Eur J Med Chem. 2010;45: 1854-67.
25. Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ, et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother. 2009;53: 1290-2.
26. Koul A, Dendouga N, Vergauwen K, et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol. 2007;3: 323-4.
27. de Jonge MR, Koymans LH, Guillemont JE, Koul A, Andries K. A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910. Proteins. 2007;67: 971-80.
28. Petrella S, Cambau E, Chauffour A, Andries K, Jarlier V, Sougakoff W. Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob Agents Chemother. 2006;50: 2853-6.
29. Gaurrand S, Desjardins S, Meyer C, et al. Conformational analysis of r207910, a new drug candidate for the treatment of tuberculosis, by a combined NMR and molecular modeling approach. Chem Biol Drug Des. 2006;68: 77-84.
30. Segala E, Sougakoff W, Nevejans-Chauffour A, Jarlier V, Petrella S. New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure. Antimicrob Agents Chemother. 2012;56: 2326-34.
31. Huitric E, Verhasselt P, Koul A, Andries K, Hoffner S, Andersson DI. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother. 2010;54: 1022-8.
32. Rouan MC, Lounis N, Gevers T, et al. Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis. Antimicrob Agents Chemother. 2012;56: 1444-51.
33. Lounis N, Gevers T, van Den Berg J, Andries K. Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob Agents Chemother. 2008;52: 3568-72.
34. Ibrahim M, Andries K, Lounis N, et al. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother. 2007;51: 1011-5.
35. Zhang T, Li SY, Williams KN, Andries K, Nuermberger EL. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med. 2011;184: 732-7.
36. Veziris N, Ibrahim M, Lounis N, Andries K, Jarlier V. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis. PLoS One. 2011;6: e17556.
37. Tasneen R, Li SY, Peloquin CA, et al. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother. 2011;55: 5485-92.
38. Shang S, Shanley CA, Caraway ML, et al. Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs. Antimicrob Agents Chemother. 2011;55: 124-31.
39. Andries K, Gevers T, Lounis N. Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis. Antimicrob Agents Chemother. 2010;54: 4540-4.
40. Veziris N, Ibrahim M, Lounis N, et al. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am J Respir Crit Care Med. 2009;179: 75-9.
41. Ibrahim M, Truffot-Pernot C, Andries K, Jarlier V, Veziris N. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am J Respir Crit Care Med. 2009;180: 553-7.
42. Lenaerts AJ, Hoff D, Aly S, et al. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrob Agents Chemother. 2007;51: 3338-45.
43. Lounis N, Veziris N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother. 2006;50: 3543-7.
44. Upadhayaya RS, Lahore SV, Sayyed AY, Dixit SS, Shinde PD, Chattopadhyaya J. Conformationally-constrained indeno[2, 1-c]quinolines-a new class of anti-mycobacterial agents. Org Biomol Chem. 2010;8: 2180-97.
45. Reddy VM, Einck L, Andries K, Nacy CA. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob Agents Chemother. 2010;54: 2840-6.
46. Diacon AH, Maritz JS, Venter A, et al. Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents. Eur J Clin Microbiol Infect Dis. 2010;29: 1561-5.
47. Dhillon J, Andries K, Phillips PP, Mitchison DA. Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells. Tuberculosis. 2010;90: 301-5.
48. Ji B, Lefrancois S, Robert J, Chauffour A, Truffot C, Jarlier V. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob Agents Chemother. 2006;50: 1921-6.
49. Sala C, Dhar N, Hartkoorn RC, et al. Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2010;54: 4150-8.
50. Upadhayaya RS, Vandavasi JK, Vasireddy NR, Sharma V, Dixit SS, Chattopadhyaya J. Design, synthesis, biological evaluation and molecular modelling studies of novel quinoline derivatives against Mycobacterium tuberculosis. Bioorg Med Chem. 2009;17: 2830-41.
51. Lounis N, Gevers T, van den Berg J, Vranckx L, Andries K. ATP synthase inhibition of Mycobacterium avium is not bactericidal. Antimicrob Agents Chemother. 2009;53: 4927-9.
52. Gelber R, Andries K, Paredes RM, Andaya CE, Burgos J. The diarylquinoline R207910 is bactericidal against Mycobacterium leprae in mice at low dose and administered intermittently. Antimicrob Agents Chemother. 2009;53: 3989-91.
53. Ji B, Chauffour A, Andries K, Jarlier V. Bactericidal activities of R207910 and other newer antimicrobial agents against Mycobacterium leprae in mice. Antimicrob Agents Chemother. 2006;50: 1558-60.
54. Huitric E, Verhasselt P, Andries K, Hoffner SE. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother. 2007;51: 4202-4.
55. Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother. 2008;52: 2831-5.
56. Diacon AH, Dawson R, Von Groote-Bidlingmaier F, et al. Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob Agents Chemother. 2013;57: 2199-203.
57. Dooley KE, Park JG, Swindells S, ACTG 5267 Study Team, et al. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. J Acquir Immune Defic Syndr. 2012;59: 455-62.
58. Svensson EM, Aweeka F, Park JG, Marzan F, Dooley KE, Karlsson MO. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients co-infected with HIV and tuberculosis. Antimicrob Agents Chemother. 2013;57: 2780-7.
59. Wallis RS, Jakubiec W, Mitton-Fry M, et al. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS One. 2012;7: e30479.
60. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-Day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet. 2012;380: 986-93.
61. Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9: 640-5.
62. Sidak Z. Confidence regions for the means of multivariate normal distributions. J Am Stat Assoc. 1967;62: 626-33.
63. Wallis RS, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet. 2010;375: 1920-37.
64. Horne DJ, Royce SE, Gooze L, et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis. 2010;10: 387-94.
65. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366: 2151-60.
66. Food and Drug Administration. E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs-questions and answers (R1). http://www. fda. gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm323656. htm. Accessed on 28 May 2013.
67. Muehlbacher M, Tripal P, Roas F, Kornhuber J. Identification of drugs inducing phospholipidosis by novel in vitro data. Chem Med Chem. 2012;7: 1925-34.
68. Owens RC Jr, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis. 2006;43: 1603-11.
69. Pugi A, Longo L, Bartoloni A, et al. Cardiovascular and metabolic safety profiles of the fluoroquinolones. Expert Opin Drug Saf. 2012;11: 53-69.
70. Lapi F, Wilchesky M, Kezouh A, Benisty JI, Ernst P, Suissa S. Fluoroquinolones and the risk of serious arrhythmia: a population-based study. Clin Infect Dis. 2012;55: 1457-65.
71. Shih TY, Pai CY, Yang P, Chang WL, Wang NC, Hu OY. A novel mechanism underlies the hepatotoxicity of pyrazinamide. Antimicrob Agents Chemother. 2013;57: 1685-90.
72. Zhou S, Chan E, Li X, Huang M. Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. Ther Clin Risk Manag. 2005;1: 3-13.
73. Klein K, Zanger UM. Pharmacogenomics of cytochrome P450 3A4: recent progress toward the "Missing Heritability" problem. Front Genet. 2013;4: 12.
74. Reasor MJ, Hastings KL, Ulrich RG. Drug-induced phospholipidosis: issues and future directions. Expert Opin Drug Saf. 2006;5: 567-83.
75. Shayman JA, Abe A. Drug induced phospholipidosis: an acquired lysosomal storage disorder. Biochim Biophys Acta. 2013;1831: 602-11.